In Brief: Biomet/E.Merck KGaA
This article was originally published in The Gray Sheet
Executive Summary
Biomet/E.Merck KGaA: Firms enter definitive agreement to create 50/50 joint venture Biomet-Merck, a $200 mil.-a-year European development and marketing organization for orthopedic products. Completion of the transaction, which the companies' announced in May ("The Gray Sheet" May 26, I&W-6) is subject to European antitrust clearance and is expected occur in early 1998. As previously announced, Biomet Chairman Niles Norblitt will head the venture as managing director and CEO...